The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Open accessAbstract
OBJECTIVE: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide-reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. METHODS: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. RESULTS: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. CONCLUSIONS: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935–1984
Hauser, W. A., Annegers, J. F., & Kurland, L. T. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb02586.x · Cited by 2,073
Prevalence of Epilepsy in Rochester, Minnesota: 1940–1980
Hauser, W. A., Annegers, J. F., & Kurland, L. T. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04675.x · Cited by 841
Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
Choudhry, N. K. (2002) · JAMA · doi:10.1001/jama.287.5.612 · Cited by 646
King, M. A., Newton, M. R., Jackson, G. D., Fitt, G. J., Mitchell, L. A., Silvapulle, M. J., & Berkovic, S. F. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03543-0 · Cited by 633
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615
Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Self-citationBrodie, M. J., Overstall, P. W., & Giorgi, L. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(99)00039-x · Cited by 459
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Cited by
Responsive cortical stimulation for the treatment of medically intractable partial epilepsy
Morrell, M. J. (2011) · Neurology · doi:10.1212/wnl.0b013e3182302056 · Cited by 1,282
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976
Guerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
Long-term treatment with responsive brain stimulation in adults with refractory partial seizures
Bergey, G. K., Morrell, M. J., Mizrahi, E. M., Goldman, A., King-Stephens, D., Nair, D., Srinivasan, S., Jobst, B., Gross, R. E., Shields, D. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001280 · Cited by 634
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Metadata
- Authors
- French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., Bergen, D., Hirtz, D., Montouris, G. D., Nespeca, M., Gidal, B., Marks, W. J., Turk, W. R., Fischer, J. H., Bourgeois, B., Wilner, A., Faught, R. E., Sachdeo, R. C., Beydoun, A., & Glauser, T. A.
- Venue
- Neurology
- Published
- 2004-04-27
- Volume
- 62
- Issue
- 8
- Pages
- 1252-1260
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2124847836
- Cited by
- 654
- References
- 74
- FWCI
- 31.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. https://app.cochat.ai/papers/10.1212/01.wnl.0000123693.82339.fc
- The paper
- French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., Bergen, D., Hirtz, D., Montouris, G. D., Nespeca, M., Gidal, B., Marks, W. J., Turk, W. R., Fischer, J. H., Bourgeois, B., . . . Glauser, T. A. (2004). Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. https://doi.org/10.1212/01.wnl.0000123693.82339.fc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.